Cobangbang Michelangelo S, Paner Bryian P, San Jose Jerome Kyle R, Isada Miguel Antonio D, Sunga Paul Anthony L
Institute of Urology, St. Luke's Medical Center, Quezon City and Global City, Philippines.
Institute of Radiology, St. Luke's Medical Center, Quezon City and Global City, Philippines.
Int Urol Nephrol. 2025 May 8. doi: 10.1007/s11255-025-04551-w.
Multiple parameters including PSA, PSAD, and PIRADS v2.1 score, are being associated in an effort to increase the overall detection rate of clinically significant prostate cancer (csPCa). This study aims to explore gray zone PSA and PSAD correlated with PIRADS score in the detection of csPCa using MRI-US fusion prostate biopsy.
Men with PSA of 4-10 who underwent prostate multiparametric MRI of the prostate (mpMRI) were divided into two groups (4-< 7 and ≥ 7-10 ng/mL) and according to PSA density (< 0.10, 0.10-0.20 and > 0.20). Subgroups according to PIRADS score were made for each group. Chi-square test was utilized for analysing the comparison of histopathology results between the PSA and PSA density subgroups per PIRADS lesion category. Using receiver-operating characteristic (ROC) curves, the diagnostic accuracy of PSA and PSAD in identifying csPCa were evaluated, and the best cutoff values were identified.
Overall detection rate of csPCa was 40.4% (146/361) in the cohort of men with gray zone PSA value. Clinically significant difference in csPCa detection rate was observed in the PSAD subgroups (p = < 0.001) while no significant difference was observed in the two groups of PSA (p = 0.387). On subgroup analysis, only the PSAD subcategories of PIRADS 4 and 5 showed significant difference (p = 0.028 and p = 0.003, respectively). Based on the ROC curve, the optimal cutoff for PSA was 6.32 with sensitivity and specificity of 65.1% and 43.3%, respectively [AUC 0.54 (0.48-0.60)]. PSAD optimal cutoff was 0.139 with sensitivity and specificity of 80.8% and 49.3%, respectively [AUC 0.67 (0.61-0.72)].
PSA and PSAD combined with PIRADS v2.1 provide more diagnostic value than when used alone and can be used to counsel men who will undergo MRI-US fusion biopsy. In the gray zone, PSAD is a more reliable diagnostic predictor of csPCa than PSA.
包括前列腺特异抗原(PSA)、前列腺特异抗原密度(PSAD)和前列腺影像报告和数据系统(PIRADS)v2.1评分在内的多个参数被联合使用,以提高临床显著前列腺癌(csPCa)的总体检出率。本研究旨在探讨在磁共振成像-超声融合前列腺活检检测csPCa中,灰色区间的PSA和PSAD与PIRADS评分的相关性。
PSA为4-10的男性患者接受前列腺多参数磁共振成像(mpMRI)检查,分为两组(4-<7和≥7-10 ng/mL),并根据PSA密度(<0.10、0.10-0.20和>0.20)进一步分组。每组再根据PIRADS评分进行亚组划分。采用卡方检验分析每个PIRADS病变类别中PSA和PSA密度亚组之间组织病理学结果的比较。使用受试者操作特征(ROC)曲线评估PSA和PSAD在识别csPCa中的诊断准确性,并确定最佳临界值。
灰色区间PSA值的男性队列中,csPCa的总体检出率为40.4%(146/361)。PSAD亚组中csPCa检出率存在临床显著差异(p = <0.001),而两组PSA之间无显著差异(p = 0.387)。亚组分析显示,仅PIRADS 4和5的PSAD亚类别存在显著差异(分别为p = 0.028和p = 0.003)。根据ROC曲线,PSA的最佳临界值为6.32,敏感性和特异性分别为65.1%和43.3%[曲线下面积(AUC)0.54(0.48-0.60)]。PSAD的最佳临界值为0.139,敏感性和特异性分别为80.8%和49.3%[AUC 0.67(0.61-0.72)]。
PSA和PSAD与PIRADS v2.1联合使用比单独使用具有更高的诊断价值,可用于为即将接受磁共振成像-超声融合活检的男性提供咨询。在灰色区间,PSAD是比PSA更可靠的csPCa诊断预测指标。